{"nctId":"NCT02141516","briefTitle":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.","startDateStruct":{"date":"2014-05"},"conditions":["Meningococcal Disease"],"count":239,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Biological: rMenB+OMV"]},{"label":"Group B","type":"EXPERIMENTAL","interventionNames":["Biological: rMenB+OMV"]},{"label":"Group C","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rMenB+OMV"]}],"interventions":[{"name":"rMenB+OMV","otherNames":[]},{"name":"rMenB+OMV","otherNames":[]},{"name":"rMenB+OMV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion criterion applicable to All Groups\n\n* Subjects aged 2 to 17 years (inclusive) at enrollment\n* weighing at least 13 Kg at the time of enrollment\n\nInclusion criterion applicable to Group A - Subjects at risk of meningococcal disease because of primary or secondary complement deficiencies\n\nInclusion criterion applicable to Group B\n\n\\- Subjects at risk of meningococcal disease because of functional or anatomic asplenia\n\nInclusion criterion applicable to Group C - healthy subjects\n\nExclusion Criteria:\n\nExclusion criteria applicable to All Groups (A, B and C)\n\n* History of any previous immunization with a meningococcal B vaccine\n* History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine\n* Known HIV infection\n* History of any progressive or severe neurologic disorder or seizure disorder\n* Contraindication to intramuscular injection or blood drawn\n* Females who are pregnant, planning a pregnancy or nursing (breastfeeding)\n* Females of childbearing potential who have not used or do not plan to use acceptable birth control measures\n* History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects\n\nExclusion criterion applicable to Groups A and B\n\n\\- Previous known or suspected disease caused by N. meningitidis in the last year.\n\nExclusion criteria applicable to Group C\n\n* Previous known or suspected disease caused by N. meningitidis\n* Known or suspected impairment/alteration of the immune system","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.","description":"Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 5 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+Outer Membrane Vesicle (OMV) NZ, administered on Day 1 and Day 61.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentages of Subjects With hSBA Titers ≥ 8 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.","description":"Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 8 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratios (GMRs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.","description":"Immunogenicity was assessed in terms of GMRs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"207","spread":null},{"groupId":"OG002","value":"228","spread":null},{"groupId":"OG003","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":null},{"groupId":"OG001","value":"2.95","spread":null},{"groupId":"OG002","value":"2.75","spread":null},{"groupId":"OG003","value":"2.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.58","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean hSBA Titers (GMTs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.","description":"Immunogenicity was assessed in terms of GMTs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"1.43","spread":null},{"groupId":"OG002","value":"1.26","spread":null},{"groupId":"OG003","value":"1.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"300","spread":null},{"groupId":"OG002","value":"290","spread":null},{"groupId":"OG003","value":"307","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"1.17","spread":null},{"groupId":"OG002","value":"1.14","spread":null},{"groupId":"OG003","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.57","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"1.06","spread":null},{"groupId":"OG003","value":"1.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.46","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentages of Subjects With Four-fold Increases in hSBA Titers Against the Serogroup B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.","description":"Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"92","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentrations (GMCs) of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.","description":"Immune responses were measured as Enzyme-linked Immunosorbent Assay (ELISA) GMCs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2039","spread":null},{"groupId":"OG001","value":"3418","spread":null},{"groupId":"OG002","value":"2973","spread":null},{"groupId":"OG003","value":"2957","spread":null}]}]}]},{"type":"PRIMARY","title":"ELISA GMRs of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.","description":"Immune responses were measured as ELISA GMRs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"138","spread":null},{"groupId":"OG002","value":"112","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Four-fold Increases in ELISA Concentrations Against the Vaccine Antigen 287-953.","description":"Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic AEs.","description":"Reactogenicity was presented in terms of percentages of subjects reporting solicited local and systemic AEs and other indicators.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"125","spread":null},{"groupId":"OG003","value":"74","spread":null},{"groupId":"OG004","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"124","spread":null},{"groupId":"OG003","value":"74","spread":null},{"groupId":"OG004","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"60","spread":null},{"groupId":"OG004","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"27","spread":null},{"groupId":"OG004","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"122","spread":null},{"groupId":"OG003","value":"71","spread":null},{"groupId":"OG004","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"46","spread":null},{"groupId":"OG004","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"35","spread":null},{"groupId":"OG004","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"27","spread":null},{"groupId":"OG004","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"38","spread":null},{"groupId":"OG004","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Number Of Subjects With Unsolicited Adverse Events (AEs).","description":"Safety was assessed as the number of subjects who reported unsolicited AEs collected from Day1 through Day 7 after any vaccination; serious adverse events (SAEs), AEs leading to withdrawal and medically attended AEs were collected throughout the study period (Day1-Day 91).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["INJECTION SITE PAIN","FATIGUE","HEADACHE","INJECTION SITE INDURATION","INJECTION SITE SWELLING"]}}}